Core Laboratories (CLB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
18 May, 2026Voting matters and shareholder proposals
Election of one new Class II Director and re-election of two current Class II Directors to serve until the 2028 annual meeting and until successors are elected and qualified.
Ratification of KPMG LLP as independent registered public accountants for the year ending December 31, 2025.
Advisory approval of executive compensation philosophy, policies, and procedures, including compensation of named executive officers as disclosed in the Compensation Discussion and Analysis.
Other business may be addressed at the annual meeting or any adjournment, at the discretion of appointed proxies.
Board of directors and corporate governance
Board recommends voting for the election and re-election of three Class II Directors.
Executive compensation and say-on-pay
Advisory vote proposed to approve the compensation philosophy, policies, and procedures for named executive officers.
Latest events from Core Laboratories
- 2025 meeting covers director elections, auditor ratification, and performance-based executive pay.CLB
Proxy filing18 May 2026 - Sequential revenue and margin growth, 21% net income rise, and share buybacks marked Q3 2025.CLB
Q3 202518 May 2026 - Proxy covers director elections, auditor ratification, and executive pay, with strong ESG focus.CLB
Proxy filing18 May 2026 - Q1 2026 revenue and margins fell on geopolitical and weather disruptions; modest Q2 rebound expected.CLB
Q1 202618 May 2026 - Votes on director re-election, auditor ratification, and executive pay set for May 2026.CLB
Proxy filing18 May 2026 - Q4 revenue up 7% year-over-year; Q1 2026 guidance: $124–$130M revenue, $0.11–$0.15 EPS.CLB
Q4 20255 Feb 2026 - Q2 2024 delivered higher margins, strong cash flow, and international growth despite U.S. softness.CLB
Q2 20243 Feb 2026 - Q3 2024 delivered 7% revenue growth, margin gains, and record-low leverage on strong international demand.CLB
Q3 202418 Jan 2026 - Full-year growth in revenue and EPS, strong cash flow, and improved leverage amid global risks.CLB
Q4 20249 Jan 2026